In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction
The Medical Letter on Drugs and Therapeutics · 11.05.2026 · 68 (1754) · 78-79
DOI: 10.58347/tml.2026.1754e ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 11.05.2026.
Abstract (Originalsprache)
The FDA has approved Vybrique (IBSA), an oral film formulation of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil, for treatment of erectile dysfunction (ED). Sildenafil oral tablets (Viagra, and generics) have been available since 1998. The manufacturer is promoting the new product as a "discreet, on-the-go" option that can be taken without water.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction. The Medical Letter on Drugs and Therapeutics, 68(1754), 78-79. https://doi.org/10.58347/tml.2026.1754e
Vancouver
In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction. The Medical Letter on Drugs and Therapeutics. 2026;68(1754):78-79. doi:10.58347/tml.2026.1754e
BibTeX
@article{euvimed2026,
title = {In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1754},
pages = {78--79},
doi = {10.58347/tml.2026.1754e}
}
EUVIMED